|
|
|
| Therapeutic Effect of Shenshu Tiaozhong Decoction on Elderly Patients with AECOPD Infected by Multi-Drug Resistant Bacteria |
| HUANG Weixia |
| Department of Traditional Chinese Medicine, Ganzhou Fifth People's Hospital, Ganzhou Jiangxi 341000 |
|
|
|
|
Abstract 【Objective】 To explore the clinical efficacy of Shenshu Tiaozhong Decoction in the treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD) complicated with multidrug resistant bacterial infection.【Methods】 A total of 82 elderly AECOPD patients with multi-drug resistant bacterial infection, who were treated in our hospital from January 2022 to April 2024, were selected and they were randomly divided into an observation group(treated with Shenshu Tiaozhong Decoction in addition to Western medicine) and a control group(treated with Western medicine alone) according to the random number table method, with 41 cases in each group. The therapeutic effects, pathogen clearance rates, adverse reactions, and changes in serum inflammatory factors, immune function indicators, and blood gas indicators before and after treatment were compared between the two groups.【Results】 After treatment, the levels of serum interleukin-6(IL-6), interleukin-8(IL-8) and the proportion of CD8+ T lymphocytes in the observation group were significantly lower than those in the control group(P<0.05), while the proportions of CD3+ and CD4+ T lymphocytes were higher than those in the control group(P<0.05). After treatment, the arterial partial pressure of oxygen(PaO2) in the observation group was higher than that in the control group, and the arterial partial pressure of carbon dioxide(PaCO2) was lower than that in the control group(P<0.05). The total effective rate and pathogen clearance rate in the observation group were significantly higher than those in the control group(P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).【Conclusion】 The application of Shenshu Tiaozhong Decoction in the treatment of elderly AECOPD patients with multi-drug resistant bacterial infection can significantly alleviate the inflammatory response, improve immune function and blood gas indicators, increase the pathogen clearance rate, and is highly safe.
|
|
Received: 20 February 2025
|
|
|
|
|
|
[1] 叶世华,翟亚波,杨继俊,等. 不同评分系统对慢性阻塞性肺疾病急性加重患者28天生存率的预测价值[J].内科急危重症杂志,2019,25(5):364-366.
[2] 张滨,陈碧珊,黄旭明,等. CX3CL1和FIB及MPV/PLT表达水平对慢性阻塞性肺疾病急性加重期患者的预后价值[J].热带医学杂志,2024,24(4):564-568.
[3] 朱小慧,张海燕,于志娟. COPD急性加重期患者不同肺部感染程度的临床特征及其与预后的相关性分析[J].临床和实验医学杂志,2023,22(16):1724-1728.
[4] 王品,何伟. 痰热清联合头孢哌酮舒巴坦治疗多重耐药鲍曼不动杆菌感染的慢性阻塞性肺疾病急性加重期痰热蕴肺证患者的疗效观察[J].世界中西医结合杂志,2023,18(10):2006-2010.
[5] 付玲,邬海桥,杨娟,等. 清肺生脉汤对AECOPD多重耐药鲍曼不动杆菌感染的临床疗效观察[J].中药新药与临床药理,2022,33(1):120-125.
[6] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等. 中国慢性阻塞性肺疾病基层诊疗与管理指南(2024年)[J].中华全科医师杂志,2024,23(6):578-602.
[7] 中华人民共和国卫生部. 医院感染诊断标准(试行)[J].中华医学杂志,2001,81(5):314-320.
[8] 中华中医药学会内科分会肺系病专业委员会. 慢性阻塞性肺疾病中医证候诊断标准(2011版)[J].中医杂志,2012,53(2):177.
[9] 国家食品药品监督管理总局.关于发布中药新药临床研究一般原则等4个技术指导原则的通告[EB/OL][2015-11-03].https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20151103120001444.html.
[10] 任姗姗,李冠臻,孙建琴,等. 老年COPD急性加重期营养状况及急性加重危险因素分析[J].中华健康管理学杂志,2022,16(4):236-240.
[11] 孙悦,赵杰,李静. 中药汤剂在治疗COPD急性加重期患者中的应用研究进展[J].中药材,2023,46(4):1059-1064.
[12] 张鸿雁. 参术调中汤治疗老年肺炎40例[J].环球中医药,2017,10(1):91-94.
[13] 张柂儇,刘海龙,王瑞琼,等. 黄芪化学成分和药理作用及Q-marker预测分析[J].中国新药杂志,2023,32(4):410-419.
[14] 李茎,郑鹏,黎攀,等. 广陈皮药理作用与临床应用研究进展[J].吉林中医药,2022,42(9):1092-1095.
[15] 左军,祁天立,胡晓阳. 茯苓化学成分及现代药理研究进展[J].中医药学报,2023,51(1):110-114. |
|
|
|
2025, Vol. 42 
